Request History

• Restore to current request
• applications/index/sort:protocol_no/direction:desc/page:4
• applications/index/page:5/sort:study_title/direction:desc
• applications/index/page:5/sort:protocol_no/direction:desc
• applications/index/sort:protocol_no/direction:desc/page:2

Session

• Config(array)
  • userAgent9c3d2c89526db53b7b69e8c9faa06145
  • time1756505856
  • countdown10

Request

Cake Params

• plugin(null)
• controllerapplications
• actionindex
• named(array)
  • sortstudy_title
  • directiondesc
  • page4
• pass(empty)
• isAjax(false)
• paging(array)
  • Application(array)
    • page4
    • current5
    • count22
    • prevPage(true)
    • nextPage(true)
    • pageCount5
    • order(array)
      • Application.study_titledesc
    • limit5
    • options(array)
      • page4
      • order(array)
        • Application.study_titledesc
      • sortstudy_title
      • directiondesc
    • paramTypenamed

Post data

• Application(empty)

Query string

No querystring data.

Cookie

To view Cookies, add CookieComponent to Controller

Current Route

• keys(array)
  • 0controller
  • 1action
• options(empty)
• defaults(array)
  • plugin(null)
• template/:controller/:action/*

Sql Logs

Logs

View Variables

• trial_statuses(array)
  • 1Recruiting
  • 2Not yet recruiting
  • 3Suspended
  • 4Stopped
  • 5Completed
  • 6In follow-up
  • 7Analysing
  • 8Writing-up
  • 9Application withdrawn
  • 10Paused or preparation for extension of study
  • 11Revoked
• applications(array)
  • 0(array)
    • Application(array)
      • id121
      • user_id29
      • application_id(null)
      • is_child0
      • trial_status_id10
      • total_sites4
      • abstract_of_study<p>\n Clinical trials are research studies conducted with human participants to evaluate the safety, effectiveness, and potential side effects of medical interventions, such as new drugs, devices, or therapies. These trials are essential for advancing medical knowledge and ensuring treatments meet rigorous standards. By following a structured approach, clinical trials provide a systematic way to assess new interventions before they are widely adopted in healthcare.</p>\n<p>\n The process of clinical trials typically progresses through multiple phases. Early phases focus on determining safety and optimal dosing in smaller groups, while later phases assess the efficacy and broader application of the intervention in larger populations. This phased approach ensures that each stage addresses specific scientific and medical questions, gradually building a comprehensive understanding of the intervention's impact.</p>\n<p>\n Ethical guidelines and scientific rigor are crucial in clinical trials to protect participants and maintain public trust. Researchers adhere to principles like informed consent and beneficence while ensuring trials are inclusive and unbiased. By bridging the gap between laboratory research and real-world medical practice, clinical trials play a critical role in improving healthcare outcomes globally.</p>\n
      • study_title<p>\n Clinical trials are research studies conducted with human participants to evaluate the safety, effectiveness, and potential side effects of medical interventions, such as new drugs, devices, or therapies. These trials are essential for advancing medical knowledge and ensuring treatments meet rigorous standards. By following a structured approach, clinical trials provide a systematic way to assess new interventions before they are widely adopted in healthcare.</p>\n<p>\n The process of clinical trials typically progresses through multiple phases. Early phases focus on determining safety and optimal dosing in smaller groups, while later phases assess the efficacy and broader application of the intervention in larger populations. This phased approach ensures that each stage addresses specific scientific and medical questions, gradually building a comprehensive understanding of the intervention's impact.</p>\n<p>\n Ethical guidelines and scientific rigor are crucial in clinical trials to protect participants and maintain public trust. Researchers adhere to principles like informed consent and beneficence while ensuring trials are inclusive and unbiased. By bridging the gap between laboratory research and real-world medical practice, clinical trials play a critical role in improving healthcare outcomes globally.</p>\n
      • laymans_summary<p>\n Clinical trials are research studies conducted with human participants to evaluate the safety, effectiveness, and potential side effects of medical interventions, such as new drugs, devices, or therapies. These trials are essential for advancing medical knowledge and ensuring treatments meet rigorous standards. By following a structured approach, clinical trials provide a systematic way to assess new interventions before they are widely adopted in healthcare.</p>\n<p>\n The process of clinical trials typically progresses through multiple phases. Early phases focus on determining safety and optimal dosing in smaller groups, while later phases assess the efficacy and broader application of the intervention in larger populations. This phased approach ensures that each stage addresses specific scientific and medical questions, gradually building a comprehensive understanding of the intervention's impact.</p>\n<p>\n Ethical guidelines and scientific rigor are crucial in clinical trials to protect participants and maintain public trust. Researchers adhere to principles like informed consent and beneficence while ensuring trials are inclusive and unbiased. By bridging the gap between laboratory research and real-world medical practice, clinical trials play a critical role in improving healthcare outcomes globally.</p>\n
      • short_titleIusto obcaecati Nam dicta veli
      • protocol_noECCT/24/11/02
      • reference_no(null)
      • version_noConsectetur qui ipsam omnis eos et voluptas
      • date_of_protocol20-11-2015
      • study_drugEst esse ex reprehenderit aute laborum illo consectetur soluta atque dolor quia numquam odit delectus et aut placeat
      • disease_conditionEt officia qui consequuntur quisquam veritatis obcaecati sunt non sit dolorum quae
      • product_type_biologicals0
      • product_type_proteins1
      • product_type_immunologicals1
      • product_type_vaccines0
      • product_type_hormones0
      • product_type_toxoid1
      • product_type_chemical1
      • product_type_medical_device1
      • product_type_chemical_nameEagan Alston
      • product_type_medical_device_nameTanisha Rowland
      • comparatorYes
      • comparator_nameBrendan Blair
      • comparator_registeredAut enim quaerat consequatur s
      • comparator_countriesRerum quis ut veniam
      • ecct_not_applicable0
      • ecct_ref_number
      • email_addressjkiprotich@intellisoftkenya.com
      • applicant_covering_letter1
      • applicant_protocol1
      • applicant_patient_information1
      • applicant_investigators_brochure1
      • applicant_investigators_cv1
      • applicant_signed_declaration1
      • applicant_financial_declaration1
      • applicant_gmp_certificate1
      • applicant_indemnity_cover1
      • applicant_opinion_letter1
      • applicant_approval_letter1
      • applicant_statement1
      • applicant_participating_countries(null)
      • applicant_addendum1
      • applicant_fees1
      • applicant_complete_form(null)
      • applicant_impd1
      • applicant_prev_data1
      • applicant_stability_data1
      • applicant_analysis_cert1
      • applicant_pictorial_sample1
      • applicant_gcp_training1
      • applicant_dsmb_charter1
      • applicant_detailed_budget1
      • applicant_indemnity_pi1
      • applicant_practice_license1
      • applicant_registration_ctr(null)
      • applicant_pan_african1
      • applicant_hard_copies(null)
      • applicant_signed_checklist1
      • statistical_analysis_plan1
      • applicant_contractual_agreement1
      • declaration_applicantSunt atque ipsum obcaecati commodo aspernatur fuga Voluptatem sed sequi cupidatat quo enim
      • declaration_date107-11-2024
      • declaration_principal_investigatorSit reprehenderit dicta beatae officia et magni deserunt ipsum in sint voluptates sed necessitatibus neque quis aspernatur esse ut
      • declaration_date214-11-2024
      • placebo_presentYes
      • study_objectives<p>\n Clinical trials are research studies conducted with human participants to evaluate the safety, effectiveness, and potential side effects of medical interventions, such as new drugs, devices, or therapies. These trials are essential for advancing medical knowledge and ensuring treatments meet rigorous standards. By following a structured approach, clinical trials provide a systematic way to assess new interventions before they are widely adopted in healthcare.</p>\n<p>\n The process of clinical trials typically progresses through multiple phases. Early phases focus on determining safety and optimal dosing in smaller groups, while later phases assess the efficacy and broader application of the intervention in larger populations. This phased approach ensures that each stage addresses specific scientific and medical questions, gradually building a comprehensive understanding of the intervention's impact.</p>\n<p>\n Ethical guidelines and scientific rigor are crucial in clinical trials to protect participants and maintain public trust. Researchers adhere to principles like informed consent and beneficence while ensuring trials are inclusive and unbiased. By bridging the gap between laboratory research and real-world medical practice, clinical trials play a critical role in improving healthcare outcomes globally.</p>\n
      • principal_inclusion_criteria<p>\n Clinical trials are research studies conducted with human participants to evaluate the safety, effectiveness, and potential side effects of medical interventions, such as new drugs, devices, or therapies. These trials are essential for advancing medical knowledge and ensuring treatments meet rigorous standards. By following a structured approach, clinical trials provide a systematic way to assess new interventions before they are widely adopted in healthcare.</p>\n<p>\n The process of clinical trials typically progresses through multiple phases. Early phases focus on determining safety and optimal dosing in smaller groups, while later phases assess the efficacy and broader application of the intervention in larger populations. This phased approach ensures that each stage addresses specific scientific and medical questions, gradually building a comprehensive understanding of the intervention's impact.</p>\n<p>\n Ethical guidelines and scientific rigor are crucial in clinical trials to protect participants and maintain public trust. Researchers adhere to principles like informed consent and beneficence while ensuring trials are inclusive and unbiased. By bridging the gap between laboratory research and real-world medical practice, clinical trials play a critical role in improving healthcare outcomes globally.</p>\n
      • principal_exclusion_criteria<p>\n Clinical trials are research studies conducted with human participants to evaluate the safety, effectiveness, and potential side effects of medical interventions, such as new drugs, devices, or therapies. These trials are essential for advancing medical knowledge and ensuring treatments meet rigorous standards. By following a structured approach, clinical trials provide a systematic way to assess new interventions before they are widely adopted in healthcare.</p>\n<p>\n The process of clinical trials typically progresses through multiple phases. Early phases focus on determining safety and optimal dosing in smaller groups, while later phases assess the efficacy and broader application of the intervention in larger populations. This phased approach ensures that each stage addresses specific scientific and medical questions, gradually building a comprehensive understanding of the intervention's impact.</p>\n<p>\n Ethical guidelines and scientific rigor are crucial in clinical trials to protect participants and maintain public trust. Researchers adhere to principles like informed consent and beneficence while ensuring trials are inclusive and unbiased. By bridging the gap between laboratory research and real-world medical practice, clinical trials play a critical role in improving healthcare outcomes globally.</p>\n
      • primary_end_points<p>\n Clinical trials are research studies conducted with human participants to evaluate the safety, effectiveness, and potential side effects of medical interventions, such as new drugs, devices, or therapies. These trials are essential for advancing medical knowledge and ensuring treatments meet rigorous standards. By following a structured approach, clinical trials provide a systematic way to assess new interventions before they are widely adopted in healthcare.</p>\n<p>\n The process of clinical trials typically progresses through multiple phases. Early phases focus on determining safety and optimal dosing in smaller groups, while later phases assess the efficacy and broader application of the intervention in larger populations. This phased approach ensures that each stage addresses specific scientific and medical questions, gradually building a comprehensive understanding of the intervention's impact.</p>\n<p>\n Ethical guidelines and scientific rigor are crucial in clinical trials to protect participants and maintain public trust. Researchers adhere to principles like informed consent and beneficence while ensuring trials are inclusive and unbiased. By bridging the gap between laboratory research and real-world medical practice, clinical trials play a critical role in improving healthcare outcomes globally.</p>\n
      • scope_diagnosis1
      • scope_prophylaxis1
      • scope_therapy1
      • scope_safety0
      • scope_efficacy1
      • scope_pharmacokinetic0
      • scope_pharmacodynamic0
      • scope_bioequivalence0
      • scope_dose_response0
      • scope_pharmacogenetic0
      • scope_pharmacogenomic1
      • scope_pharmacoecomomic0
      • scope_others1
      • scope_others_specifyLorem voluptatem Ab
      • trial_human_pharmacology1
      • trial_administration_humans1
      • trial_bioequivalence_study1
      • trial_other1
      • trial_other_specifySimilique tempore c
      • trial_therapeutic_exploratory1
      • trial_therapeutic_confirmatory1
      • trial_therapeutic_use1
      • design_controlledYes
      • site_capacity(null)
      • staff_numbers<p>\n Clinical trials are research studies conducted with human participants to evaluate the safety, effectiveness, and potential side effects of medical interventions, such as new drugs, devices, or therapies. These trials are essential for advancing medical knowledge and ensuring treatments meet rigorous standards. By following a structured approach, clinical trials provide a systematic way to assess new interventions before they are widely adopted in healthcare.</p>\n<p>\n The process of clinical trials typically progresses through multiple phases. Early phases focus on determining safety and optimal dosing in smaller groups, while later phases assess the efficacy and broader application of the intervention in larger populations. This phased approach ensures that each stage addresses specific scientific and medical questions, gradually building a comprehensive understanding of the intervention's impact.</p>\n<p>\n Ethical guidelines and scientific rigor are crucial in clinical trials to protect participants and maintain public trust. Researchers adhere to principles like informed consent and beneficence while ensuring trials are inclusive and unbiased. By bridging the gap between laboratory research and real-world medical practice, clinical trials play a critical role in improving healthcare outcomes globally.</p>\n
      • other_details_explanation<p>\n Clinical trials are research studies conducted with human participants to evaluate the safety, effectiveness, and potential side effects of medical interventions, such as new drugs, devices, or therapies. These trials are essential for advancing medical knowledge and ensuring treatments meet rigorous standards. By following a structured approach, clinical trials provide a systematic way to assess new interventions before they are widely adopted in healthcare.</p>\n<p>\n The process of clinical trials typically progresses through multiple phases. Early phases focus on determining safety and optimal dosing in smaller groups, while later phases assess the efficacy and broader application of the intervention in larger populations. This phased approach ensures that each stage addresses specific scientific and medical questions, gradually building a comprehensive understanding of the intervention's impact.</p>\n<p>\n Ethical guidelines and scientific rigor are crucial in clinical trials to protect participants and maintain public trust. Researchers adhere to principles like informed consent and beneficence while ensuring trials are inclusive and unbiased. By bridging the gap between laboratory research and real-world medical practice, clinical trials play a critical role in improving healthcare outcomes globally.</p>\n
      • other_details_regulatory_notapproved<p>\n Clinical trials are research studies conducted with human participants to evaluate the safety, effectiveness, and potential side effects of medical interventions, such as new drugs, devices, or therapies. These trials are essential for advancing medical knowledge and ensuring treatments meet rigorous standards. By following a structured approach, clinical trials provide a systematic way to assess new interventions before they are widely adopted in healthcare.</p>\n<p>\n The process of clinical trials typically progresses through multiple phases. Early phases focus on determining safety and optimal dosing in smaller groups, while later phases assess the efficacy and broader application of the intervention in larger populations. This phased approach ensures that each stage addresses specific scientific and medical questions, gradually building a comprehensive understanding of the intervention's impact.</p>\n<p>\n Ethical guidelines and scientific rigor are crucial in clinical trials to protect participants and maintain public trust. Researchers adhere to principles like informed consent and beneficence while ensuring trials are inclusive and unbiased. By bridging the gap between laboratory research and real-world medical practice, clinical trials play a critical role in improving healthcare outcomes globally.</p>\n
      • other_details_regulatory_approved<p>\n Clinical trials are research studies conducted with human participants to evaluate the safety, effectiveness, and potential side effects of medical interventions, such as new drugs, devices, or therapies. These trials are essential for advancing medical knowledge and ensuring treatments meet rigorous standards. By following a structured approach, clinical trials provide a systematic way to assess new interventions before they are widely adopted in healthcare.</p>\n<p>\n The process of clinical trials typically progresses through multiple phases. Early phases focus on determining safety and optimal dosing in smaller groups, while later phases assess the efficacy and broader application of the intervention in larger populations. This phased approach ensures that each stage addresses specific scientific and medical questions, gradually building a comprehensive understanding of the intervention's impact.</p>\n<p>\n Ethical guidelines and scientific rigor are crucial in clinical trials to protect participants and maintain public trust. Researchers adhere to principles like informed consent and beneficence while ensuring trials are inclusive and unbiased. By bridging the gap between laboratory research and real-world medical practice, clinical trials play a critical role in improving healthcare outcomes globally.</p>\n
      • other_details_regulatory_rejected<p>\n Clinical trials are research studies conducted with human participants to evaluate the safety, effectiveness, and potential side effects of medical interventions, such as new drugs, devices, or therapies. These trials are essential for advancing medical knowledge and ensuring treatments meet rigorous standards. By following a structured approach, clinical trials provide a systematic way to assess new interventions before they are widely adopted in healthcare.</p>\n<p>\n The process of clinical trials typically progresses through multiple phases. Early phases focus on determining safety and optimal dosing in smaller groups, while later phases assess the efficacy and broader application of the intervention in larger populations. This phased approach ensures that each stage addresses specific scientific and medical questions, gradually building a comprehensive understanding of the intervention's impact.</p>\n<p>\n Ethical guidelines and scientific rigor are crucial in clinical trials to protect participants and maintain public trust. Researchers adhere to principles like informed consent and beneficence while ensuring trials are inclusive and unbiased. By bridging the gap between laboratory research and real-world medical practice, clinical trials play a critical role in improving healthcare outcomes globally.</p>\n
      • other_details_regulatory_halted<p>\n Clinical trials are research studies conducted with human participants to evaluate the safety, effectiveness, and potential side effects of medical interventions, such as new drugs, devices, or therapies. These trials are essential for advancing medical knowledge and ensuring treatments meet rigorous standards. By following a structured approach, clinical trials provide a systematic way to assess new interventions before they are widely adopted in healthcare.</p>\n<p>\n The process of clinical trials typically progresses through multiple phases. Early phases focus on determining safety and optimal dosing in smaller groups, while later phases assess the efficacy and broader application of the intervention in larger populations. This phased approach ensures that each stage addresses specific scientific and medical questions, gradually building a comprehensive understanding of the intervention's impact.</p>\n<p>\n Ethical guidelines and scientific rigor are crucial in clinical trials to protect participants and maintain public trust. Researchers adhere to principles like informed consent and beneficence while ensuring trials are inclusive and unbiased. By bridging the gap between laboratory research and real-world medical practice, clinical trials play a critical role in improving healthcare outcomes globally.</p>\n
      • estimated_duration3
      • design_controlled_randomisedNo
      • design_controlled_openNo
      • design_controlled_single_blindYes
      • design_controlled_double_blindNo
      • design_controlled_parallel_groupYes
      • design_controlled_cross_overNo
      • design_controlled_otherYes
      • design_controlled_specifyEum labore saepe rem quia sint dolore porro magni nihil facilis doloribus sint ipsa et officia distinctio Aut
      • design_controlled_comparatorBlanditiis quaerat est ex
      • design_controlled_other_medicinalYes
      • design_controlled_placeboNo
      • design_controlled_medicinal_otherNo
      • design_controlled_medicinal_specify
      • single_site_member_stateNo
      • location_of_area
      • single_site_physical_address
      • single_site_contact_person
      • single_site_telephone
      • multiple_sites_member_stateNo
      • multiple_countriesYes
      • multiple_member_states4
      • number_of_sites
      • multi_country_listHarum hic tempora ne
      • data_monitoring_committeeYes
      • total_enrolment_per_siteNon ex beatae a dele
      • total_participants_worldwideExcepteur maxime nisi voluptatem minim ad quisquam harum dolore doloribus quia sunt consequatur Perspiciatis doloribus sed
      • population_less_than_18_yearsYes
      • population_uteroNo
      • population_preterm_newbornYes
      • population_newbornYes
      • population_infant_and_toddlerNo
      • population_childrenNo
      • population_adolescentNo
      • population_above_18Yes
      • population_adultNo
      • population_elderlyYes
      • gender_female1
      • gender_male0
      • subjects_healthyNo
      • subjects_patientsNo
      • subjects_vulnerable_populationsYes
      • subjects_women_child_bearingNo
      • subjects_women_using_contraceptionYes
      • subjects_pregnant_womenNo
      • subjects_nursing_womenNo
      • subjects_emergency_situationNo
      • subjects_incapable_consentNo
      • subjects_specify
      • subjects_othersYes
      • subjects_others_specifyExercitation perspic
      • investigator1_given_nameRachel Hewitt
      • investigator1_middle_nameKylynn Townsend
      • investigator1_family_nameOctavia Acosta
      • investigator1_qualificationDolores quae ut corrupti voluptatem in aliquip animi esse aliqua Dicta sapiente ipsam debitis impedit nobis
      • investigator1_professional_addressVel aut quis in consectetur incidunt placeat sint consectetur sint dolores commodi
      • investigator1_telephone+1 (618) 138-4296
      • investigator1_emailbezic@mailinator.com
      • organisations_transferred_Yes
      • number_participantsSuscipit adipisicing
      • notification<p>\n Clinical trials are research studies conducted with human participants to evaluate the safety, effectiveness, and potential side effects of medical interventions, such as new drugs, devices, or therapies. These trials are essential for advancing medical knowledge and ensuring treatments meet rigorous standards. By following a structured approach, clinical trials provide a systematic way to assess new interventions before they are widely adopted in healthcare.</p>\n<p>\n The process of clinical trials typically progresses through multiple phases. Early phases focus on determining safety and optimal dosing in smaller groups, while later phases assess the efficacy and broader application of the intervention in larger populations. This phased approach ensures that each stage addresses specific scientific and medical questions, gradually building a comprehensive understanding of the intervention's impact.</p>\n<p>\n Ethical guidelines and scientific rigor are crucial in clinical trials to protect participants and maintain public trust. Researchers adhere to principles like informed consent and beneficence while ensuring trials are inclusive and unbiased. By bridging the gap between laboratory research and real-world medical practice, clinical trials play a critical role in improving healthcare outcomes globally.</p>\n
      • approval_date29-11-2024
      • submitted1
      • deleted0
      • deleted_date(null)
      • deactivated0
      • date_submitted20-11-2024
      • unsubmitted0
      • initial_date_submitted(null)
      • admin_stopped0
      • admin_stopped_reason(null)
      • approved2
      • approved_reasonTest
      • approved_date(null)
      • final_report<p>\n test sample</p>\n
      • implication_results<p>\n sample</p>\n
      • quantity_imported2
      • quantity_dispensed3
      • quantity_destroyed4
      • quantity_exported1
      • balance_site2
      • final_date2025-08-05
      • ecitizen_invoice324265
      • modified2025-08-05 08:08:23
      • created2024-10-18 08:02:13
    • InvestigatorContact(array)
      • 0(array)
        • id79
        • application_id121
        • given_nameLinus Sexton
        • middle_nameOri Hill
        • family_nameJacob Mckay
        • qualificationIllum doloribus soluta numquam omnis elit quibusdam non
        • professional_addressAliquam fugiat qui officia veniam excepturi et nisi neque enim aliquip tempora
        • telephone+1 (188) 739-1402
        • emailmipaj@mailinator.com
        • created2024-11-20 09:47:01
        • modified2024-11-20 10:15:06
    • SiteDetail(array)
      • 0(array)
        • id94
        • application_id121
        • county_id(null)
        • site_name
        • physical_address
        • contact_details
        • contact_person
        • site_capacity(null)
        • misc(null)
        • created2013-04-16 14:25:04
        • modified2024-11-20 10:15:06
        • County(empty)
    • Sponsor(array)
      • 0(array)
        • id32
        • application_id121
        • sponsorAnim obcaecati dolorem cillum qui nemo in vitae ea veritatis
        • sponsor_typeIndustry
        • contact_personFugiat corporis inventore non commodo nesciunt ut non doloremque optio voluptates minima recusandae Veritatis reprehenderit velit commodo
        • addressAutem odio eaque quia est blanditiis reiciendis commodi et adipisicing enim voluptate
        • telephone_number+1 (343) 625-7251
        • fax_number+1 (936) 324-2944
        • cell_number+1 (942) 698-1737
        • email_addressvugit@mailinator.com
        • created2024-11-20 09:47:01
        • modified2024-11-20 10:15:06
  • 1(array)
    • Application(array)
      • id120
      • user_id82
      • application_id(null)
      • is_child0
      • trial_status_id(null)
      • total_sites1
      • abstract_of_study<p>\n studyabstract</p>\n
      • study_title<p>\n abstract 123</p>\n
      • laymans_summary<p>\n layman</p>\n
      • short_titleuser
      • protocol_noECCT/24/10/02
      • reference_no(null)
      • version_no2
      • date_of_protocol09-10-2024
      • study_drugstudydrug
      • disease_conditionmalaria
      • product_type_biologicals1
      • product_type_proteins1
      • product_type_immunologicals0
      • product_type_vaccines0
      • product_type_hormones0
      • product_type_toxoid0
      • product_type_chemical0
      • product_type_medical_device0
      • product_type_chemical_name
      • product_type_medical_device_name
      • comparatorNo
      • comparator_name
      • comparator_registered
      • comparator_countries
      • ecct_not_applicable0
      • ecct_ref_number
      • email_addresslchepkwony@intellisoftkenya.com
      • applicant_covering_letter1
      • applicant_protocol1
      • applicant_patient_information1
      • applicant_investigators_brochure1
      • applicant_investigators_cv1
      • applicant_signed_declaration1
      • applicant_financial_declaration1
      • applicant_gmp_certificate1
      • applicant_indemnity_cover1
      • applicant_opinion_letter1
      • applicant_approval_letter1
      • applicant_statement1
      • applicant_participating_countries(null)
      • applicant_addendum1
      • applicant_fees1
      • applicant_complete_form(null)
      • applicant_impd1
      • applicant_prev_data1
      • applicant_stability_data1
      • applicant_analysis_cert1
      • applicant_pictorial_sample1
      • applicant_gcp_training1
      • applicant_dsmb_charter1
      • applicant_detailed_budget1
      • applicant_indemnity_pi1
      • applicant_practice_license1
      • applicant_registration_ctr(null)
      • applicant_pan_african1
      • applicant_hard_copies(null)
      • applicant_signed_checklist1
      • statistical_analysis_plan1
      • applicant_contractual_agreement1
      • declaration_applicantDeleniti et autem ea omnis
      • declaration_date104-05-2023
      • declaration_principal_investigatorQuaerat aspernatur consequatur non voluptas inventore ad officiis do consequatur voluptates enim asperiores minim illum
      • declaration_date218-01-2014
      • placebo_presentYes
      • study_objectives<p>\n objective</p>\n
      • principal_inclusion_criteria<p>\n inclusion</p>\n
      • principal_exclusion_criteria<p>\n exclusion</p>\n
      • primary_end_points<p>\n end point</p>\n
      • scope_diagnosis1
      • scope_prophylaxis1
      • scope_therapy0
      • scope_safety1
      • scope_efficacy0
      • scope_pharmacokinetic0
      • scope_pharmacodynamic0
      • scope_bioequivalence1
      • scope_dose_response0
      • scope_pharmacogenetic0
      • scope_pharmacogenomic0
      • scope_pharmacoecomomic1
      • scope_others1
      • scope_others_specifySit ut lorem ut vel
      • trial_human_pharmacology1
      • trial_administration_humans0
      • trial_bioequivalence_study1
      • trial_other0
      • trial_other_specify
      • trial_therapeutic_exploratory0
      • trial_therapeutic_confirmatory0
      • trial_therapeutic_use1
      • design_controlledYes
      • site_capacity(null)
      • staff_numbers<p>\n 1234</p>\n
      • other_details_explanation<p>\n explained</p>\n
      • other_details_regulatory_notapproved<p>\n reg</p>\n
      • other_details_regulatory_approved<p>\n reg</p>\n
      • other_details_regulatory_rejected<p>\n reg</p>\n
      • other_details_regulatory_halted
      • estimated_durationEsse ducimus possimus aut architecto esse in dolor illum tempor cillum
      • design_controlled_randomisedNo
      • design_controlled_openNo
      • design_controlled_single_blindNo
      • design_controlled_double_blindNo
      • design_controlled_parallel_groupNo
      • design_controlled_cross_overNo
      • design_controlled_otherYes
      • design_controlled_specifyNeque deserunt nostrud minima aut sed enim veniam odit assumenda officia
      • design_controlled_comparatorRepellendus Sed temporib
      • design_controlled_other_medicinalYes
      • design_controlled_placeboYes
      • design_controlled_medicinal_otherNo
      • design_controlled_medicinal_specify
      • single_site_member_stateNo
      • location_of_area
      • single_site_physical_address
      • single_site_contact_person
      • single_site_telephone
      • multiple_sites_member_stateYes
      • multiple_countriesYes
      • multiple_member_states772
      • number_of_sites961
      • multi_country_listDelectus suscipit e
      • data_monitoring_committeeNo
      • total_enrolment_per_siteDolor sint animi er
      • total_participants_worldwideCorrupti laudantium similique cupiditate nostrum rerum est vero laborum adipisicing
      • population_less_than_18_yearsYes
      • population_uteroNo
      • population_preterm_newbornNo
      • population_newbornYes
      • population_infant_and_toddlerNo
      • population_childrenNo
      • population_adolescentYes
      • population_above_18Yes
      • population_adultYes
      • population_elderlyNo
      • gender_female1
      • gender_male0
      • subjects_healthyNo
      • subjects_patientsNo
      • subjects_vulnerable_populationsYes
      • subjects_women_child_bearingNo
      • subjects_women_using_contraceptionYes
      • subjects_pregnant_womenNo
      • subjects_nursing_womenYes
      • subjects_emergency_situationYes
      • subjects_incapable_consentYes
      • subjects_specifyVoluptatum perspicia
      • subjects_othersNo
      • subjects_others_specify
      • investigator1_given_nameBrent Mcknight
      • investigator1_middle_nameNicole Gross
      • investigator1_family_nameCharles Crane
      • investigator1_qualificationId adipisci commodo repellendus Dolor enim iste et quam deserunt id ut ullamco
      • investigator1_professional_addressQuia eius aut adipisicing rerum aut ad tempora necessitatibus cumque nisi at
      • investigator1_telephone+1 (795) 542-5315
      • investigator1_emaildudahabewy@mailinator.com
      • organisations_transferred_No
      • number_participantsVoluptatem ut nisi e
      • notification
      • approval_date19-11-2024
      • submitted1
      • deleted0
      • deleted_date(null)
      • deactivated0
      • date_submitted23-10-2024
      • unsubmitted0
      • initial_date_submitted(null)
      • admin_stopped0
      • admin_stopped_reason(null)
      • approved2
      • approved_reasonApproved Here successfully
      • approved_date(null)
      • final_report(null)
      • implication_results(null)
      • quantity_imported(null)
      • quantity_dispensed(null)
      • quantity_destroyed(null)
      • quantity_exported(null)
      • balance_site(null)
      • final_date(null)
      • ecitizen_invoice324112
      • modified2024-11-19 16:25:21
      • created2024-10-17 12:04:18
    • InvestigatorContact(array)
      • 0(array)
        • id72
        • application_id120
        • given_nameIrene Peterson
        • middle_nameMelinda Farrell
        • family_nameMarah Bush
        • qualificationId ipsa qui obcaecati sit iste eu reiciendis pariatur Possimus temporibus consequatur et culpa ad tenetur iusto inventore nihil labore
        • professional_addressCorporis ut quo libero ut ullam error
        • telephone+1 (524) 915-1935
        • emailpypamyhezu@mailinator.com
        • created2024-10-17 12:49:37
        • modified2024-10-23 15:04:34
    • SiteDetail(array)
      • 0(array)
        • id1704
        • application_id120
        • county_id20
        • site_nameHarriet Battle
        • physical_addressQuae nulla sunt culpa beatae fugiat dolor quae labore similique in quae dignissimos a tempore ut tempore
        • contact_detailsP.O. Box 5325
        • contact_personNisi eum dolorem fugiat ullam dolore nemo laudantium aut autem natus similique numquam deserunt omnis quod officia
        • site_capacity(null)
        • misc(null)
        • created2024-10-17 12:49:37
        • modified2024-10-23 15:04:34
        • County(array)
          • id20
          • county_nameKirinyaga
          • created2012-06-15 10:24:22
          • modified2012-06-15 10:24:22
    • Sponsor(array)
      • 0(array)
        • id29
        • application_id120
        • sponsorFuga Aut qui est consequatur consectetur dolorem qui blanditiis saepe natus maiores ea repellendus Velit quia ullamco
        • sponsor_typeResearch Institution
        • contact_personNon corrupti reiciendis placeat elit aut voluptatibus optio labore excepteur
        • addressConsectetur ut ipsum quia quos magni
        • telephone_number+1 (367) 517-6326
        • fax_number+1 (961) 772-5694
        • cell_number+1 (895) 885-1686
        • email_addressrimumaxy@mailinator.com
        • created2024-10-17 12:49:37
        • modified2024-10-23 15:04:34
  • 2(array)
    • Application(array)
      • id118
      • user_id29
      • application_id(null)
      • is_child0
      • trial_status_id7
      • total_sites5
      • abstract_of_study<p>\n <em>Background:</em> The Novacov-24 virus, a newly identified respiratory pathogen, has raised global health concerns due to its rapid spread and potential for severe illness. Effective antiviral treatments are urgently needed to reduce symptom severity, prevent complications, and lower hospitalization rates.</p>\n<p>\n <em>Objective:</em> This randomized, double-blind, placebo-controlled clinical trial aims to evaluate the efficacy and safety of <em>Virunex-3</em>, a novel antiviral agent, in reducing the severity and duration of symptoms in patients infected with the Novacov-24 virus.</p>\n<p>\n <em>Methods:</em> A total of 500 adult participants with confirmed Novacov-24 infection will be enrolled. Participants will be randomly assigned to receive either <em>Virunex-3</em> (100 mg orally, once daily for 7 days) or a placebo. Primary outcomes will include the reduction of viral load and symptom resolution within 7 days. Secondary outcomes will assess hospitalization rates, need for mechanical ventilation, and mortality. Adverse events and treatment safety will also be monitored.</p>\n<p>\n <em>Expected Outcomes:</em> The study aims to determine whether <em>Virunex-3</em> can effectively reduce symptoms and improve patient recovery while ensuring safety. If successful, this trial could contribute to the development of a new standard of care for Novacov-24 infection.</p>\n<p>\n <em>Conclusion:</em> By assessing both the effectiveness and safety of <em>Virunex-3</em>, this trial will provide valuable insights into managing Novacov-24 and preventing severe health outcomes.</p>\n
      • study_title<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • laymans_summary<p>\n This study is designed to test a new antiviral medication called <em>Virunex-3</em> to see if it can help people recover faster from an illness caused by a newly identified virus called <em>Novacov-24</em>. Participants in the study will either receive <em>Virunex-3</em> or a placebo (a pill with no active ingredients) without knowing which one they are getting. The goal is to find out if <em>Virunex-3</em> can reduce symptoms more quickly, lower the need for hospital care, and prevent serious complications. The results will help doctors understand if this new treatment is safe and effective for fighting the virus.</p>\n
      • short_titleVirunex-3 Trial for Novacov-24
      • protocol_noECCT/25/01/09- KPCTYn
      • reference_no1234redwsqa
      • version_nov1
      • date_of_protocol01-01-2025
      • study_drugVirunex-3
      • disease_conditionNovacov-24 Virus Infection
      • product_type_biologicals1
      • product_type_proteins0
      • product_type_immunologicals1
      • product_type_vaccines0
      • product_type_hormones0
      • product_type_toxoid0
      • product_type_chemical0
      • product_type_medical_device0
      • product_type_chemical_name
      • product_type_medical_device_name
      • comparatorNo
      • comparator_name
      • comparator_registered
      • comparator_countries
      • ecct_not_applicable0
      • ecct_ref_number
      • email_addressjkiprotich@intellisoftkenya.com
      • applicant_covering_letter1
      • applicant_protocol1
      • applicant_patient_information1
      • applicant_investigators_brochure1
      • applicant_investigators_cv1
      • applicant_signed_declaration1
      • applicant_financial_declaration1
      • applicant_gmp_certificate1
      • applicant_indemnity_cover1
      • applicant_opinion_letter1
      • applicant_approval_letter1
      • applicant_statement1
      • applicant_participating_countries(null)
      • applicant_addendum1
      • applicant_fees1
      • applicant_complete_form(null)
      • applicant_impd1
      • applicant_prev_data1
      • applicant_stability_data1
      • applicant_analysis_cert1
      • applicant_pictorial_sample1
      • applicant_gcp_training1
      • applicant_dsmb_charter1
      • applicant_detailed_budget1
      • applicant_indemnity_pi1
      • applicant_practice_license1
      • applicant_registration_ctr(null)
      • applicant_pan_african1
      • applicant_hard_copies(null)
      • applicant_signed_checklist1
      • statistical_analysis_plan1
      • applicant_contractual_agreement1
      • declaration_applicantOfficia quasi sunt ab ducimus eaque consectetur aut hic modi omnis
      • declaration_date110-01-2025
      • declaration_principal_investigatorCupidatat consectetur consequuntur fugiat labore necessitatibus dolore est saepe dolorem cumque aliquid aliqua In id quibusdam accusamus
      • declaration_date209-01-2025
      • placebo_presentYes
      • study_objectives<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • principal_inclusion_criteria<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • principal_exclusion_criteria<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • primary_end_points<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • scope_diagnosis1
      • scope_prophylaxis0
      • scope_therapy0
      • scope_safety0
      • scope_efficacy0
      • scope_pharmacokinetic0
      • scope_pharmacodynamic1
      • scope_bioequivalence0
      • scope_dose_response1
      • scope_pharmacogenetic0
      • scope_pharmacogenomic0
      • scope_pharmacoecomomic1
      • scope_others1
      • scope_others_specifyIn odit voluptate fu
      • trial_human_pharmacology0
      • trial_administration_humans1
      • trial_bioequivalence_study0
      • trial_other1
      • trial_other_specifyVoluptas veniam ut
      • trial_therapeutic_exploratory0
      • trial_therapeutic_confirmatory1
      • trial_therapeutic_use1
      • design_controlledYes
      • site_capacity(null)
      • staff_numbers<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • other_details_explanation<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • other_details_regulatory_notapproved<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • other_details_regulatory_approved<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • other_details_regulatory_rejected
      • other_details_regulatory_halted
      • estimated_durationTempore id architecto quaerat ad vel
      • design_controlled_randomisedNo
      • design_controlled_openYes
      • design_controlled_single_blindNo
      • design_controlled_double_blindYes
      • design_controlled_parallel_groupNo
      • design_controlled_cross_overYes
      • design_controlled_otherYes
      • design_controlled_specifyQuo magna rerum dolor et atque adipisci esse nostrum
      • design_controlled_comparatorAut qui perspiciatis rei
      • design_controlled_other_medicinalNo
      • design_controlled_placeboNo
      • design_controlled_medicinal_otherYes
      • design_controlled_medicinal_specifySed iste tempore quia tempore tempor repudiandae molestias explicabo Omnis cum et asperiores vel est
      • single_site_member_stateNo
      • location_of_area
      • single_site_physical_address
      • single_site_contact_person
      • single_site_telephone
      • multiple_sites_member_stateYes
      • multiple_countriesYes
      • multiple_member_states668
      • number_of_sites9
      • multi_country_listAdipisicing et numqu
      • data_monitoring_committeeYes
      • total_enrolment_per_siteVitae voluptatem se
      • total_participants_worldwideAutem ut aut commodo quas eaque velit dolore proident adipisicing eaque lorem sunt doloribus dolor quo pariatur
      • population_less_than_18_yearsYes
      • population_uteroYes
      • population_preterm_newbornYes
      • population_newbornYes
      • population_infant_and_toddlerNo
      • population_childrenYes
      • population_adolescentNo
      • population_above_18Yes
      • population_adultNo
      • population_elderlyNo
      • gender_female1
      • gender_male0
      • subjects_healthyNo
      • subjects_patientsYes
      • subjects_vulnerable_populationsYes
      • subjects_women_child_bearingNo
      • subjects_women_using_contraceptionYes
      • subjects_pregnant_womenNo
      • subjects_nursing_womenYes
      • subjects_emergency_situationNo
      • subjects_incapable_consentYes
      • subjects_specifyId tempora omnis vol
      • subjects_othersYes
      • subjects_others_specifyUllam laborum Eos
      • investigator1_given_nameIlliana Ferguson
      • investigator1_middle_nameAllen Fox
      • investigator1_family_nameYolanda Rivera
      • investigator1_qualificationAut labore non sed sed aut iusto et asperiores eu ut ut do qui ullam aut obcaecati earum modi in
      • investigator1_professional_addressEst doloremque dolores adipisicing quidem laboris voluptates vitae ex
      • investigator1_telephone+1 (621) 831-1153
      • investigator1_emailqeryrilu@mailinator.com
      • organisations_transferred_Yes
      • number_participantsMinim dolor commodo
      • notification
      • approval_date13-01-2025
      • submitted1
      • deleted0
      • deleted_date(null)
      • deactivated0
      • date_submitted07-01-2025
      • unsubmitted1
      • initial_date_submitted07-01-2025
      • admin_stopped0
      • admin_stopped_reason(null)
      • approved2
      • approved_reasonThis is approved
      • approved_date(null)
      • final_report(null)
      • implication_results(null)
      • quantity_imported(null)
      • quantity_dispensed(null)
      • quantity_destroyed(null)
      • quantity_exported(null)
      • balance_site(null)
      • final_date(null)
      • ecitizen_invoice324073
      • modified2025-02-14 10:11:54
      • created2024-10-17 10:21:33
    • InvestigatorContact(array)
      • 0(array)
        • id87
        • application_id118
        • given_nameHiroko Lewis
        • middle_nameTatyana Medina
        • family_nameCastor Gallagher
        • qualificationQuis molestiae voluptate aut aliquam velit est consequat Asperiores possimus et neque molestias aliqua Omnis voluptas non dolor nulla laudantium
        • professional_addressNisi qui dolor optio tempore quisquam laborum Suscipit
        • telephone+1 (322) 766-3057
        • emailtipyhuqo@mailinator.com
        • created2025-01-13 12:13:08
        • modified2025-02-06 10:49:58
    • SiteDetail(array)
      • 0(array)
        • id1707
        • application_id118
        • county_id38
        • site_nameAhmed Trujillo
        • physical_addressDolorum dolores necessitatibus minus magna quo velit eveniet temporibus accusantium eveniet maxime reprehenderit consectetur ipsum ea aut
        • contact_detailsP.O. Box 10
        • contact_personExcepturi culpa dolore vero ut blanditiis aliquam error exercitation dolore reiciendis harum molestiae molestiae magnam fugit
        • site_capacity(null)
        • misc(null)
        • created2025-01-13 12:13:08
        • modified2025-02-06 10:49:58
        • County(array)
          • id38
          • county_nameVihiga
          • created2012-06-15 10:26:37
          • modified2012-06-15 10:26:37
    • Sponsor(array)
      • 0(array)
        • id36
        • application_id118
        • sponsorEnim sint voluptatem eos nobis reiciendis dolore et qui corrupti quod minim pariatur Possimus
        • sponsor_typeLocal Kenyan Investigator
        • contact_personDolorem mollitia id quis provident error voluptatem voluptate
        • addressDolore laborum delectus dolor corrupti rerum aut magnam impedit quia cillum et cupiditate aliquid sapiente
        • telephone_number+1 (666) 325-1183
        • fax_number+1 (314) 248-5575
        • cell_number+1 (134) 102-6236
        • email_addresstuhokelyh@mailinator.com
        • created2025-01-13 12:13:08
        • modified2025-02-06 10:49:58
  • 3(array)
    • Application(array)
      • id158
      • user_id86
      • application_id118
      • is_child1
      • trial_status_id7
      • total_sites5
      • abstract_of_study<p>\n <em>Background:</em> The Novacov-24 virus, a newly identified respiratory pathogen, has raised global health concerns due to its rapid spread and potential for severe illness. Effective antiviral treatments are urgently needed to reduce symptom severity, prevent complications, and lower hospitalization rates.</p>\n<p>\n <em>Objective:</em> This randomized, double-blind, placebo-controlled clinical trial aims to evaluate the efficacy and safety of <em>Virunex-3</em>, a novel antiviral agent, in reducing the severity and duration of symptoms in patients infected with the Novacov-24 virus.</p>\n<p>\n <em>Methods:</em> A total of 500 adult participants with confirmed Novacov-24 infection will be enrolled. Participants will be randomly assigned to receive either <em>Virunex-3</em> (100 mg orally, once daily for 7 days) or a placebo. Primary outcomes will include the reduction of viral load and symptom resolution within 7 days. Secondary outcomes will assess hospitalization rates, need for mechanical ventilation, and mortality. Adverse events and treatment safety will also be monitored.</p>\n<p>\n <em>Expected Outcomes:</em> The study aims to determine whether <em>Virunex-3</em> can effectively reduce symptoms and improve patient recovery while ensuring safety. If successful, this trial could contribute to the development of a new standard of care for Novacov-24 infection.</p>\n<p>\n <em>Conclusion:</em> By assessing both the effectiveness and safety of <em>Virunex-3</em>, this trial will provide valuable insights into managing Novacov-24 and preventing severe health outcomes.</p>\n
      • study_title<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • laymans_summary<p>\n This study is designed to test a new antiviral medication called <em>Virunex-3</em> to see if it can help people recover faster from an illness caused by a newly identified virus called <em>Novacov-24</em>. Participants in the study will either receive <em>Virunex-3</em> or a placebo (a pill with no active ingredients) without knowing which one they are getting. The goal is to find out if <em>Virunex-3</em> can reduce symptoms more quickly, lower the need for hospital care, and prevent serious complications. The results will help doctors understand if this new treatment is safe and effective for fighting the virus.</p>\n
      • short_titleVirunex-3 Trial for Novacov-24
      • protocol_noECCT/25/01/09 - A
      • reference_no1234redwsqa
      • version_nov1
      • date_of_protocol01-01-2025
      • study_drugVirunex-3
      • disease_conditionNovacov-24 Virus Infection
      • product_type_biologicals1
      • product_type_proteins0
      • product_type_immunologicals1
      • product_type_vaccines0
      • product_type_hormones0
      • product_type_toxoid0
      • product_type_chemical0
      • product_type_medical_device0
      • product_type_chemical_name
      • product_type_medical_device_name
      • comparatorNo
      • comparator_name
      • comparator_registered
      • comparator_countries
      • ecct_not_applicable0
      • ecct_ref_number
      • email_addressjkiprotich@intellisoftkenya.com
      • applicant_covering_letter1
      • applicant_protocol1
      • applicant_patient_information1
      • applicant_investigators_brochure1
      • applicant_investigators_cv1
      • applicant_signed_declaration1
      • applicant_financial_declaration1
      • applicant_gmp_certificate1
      • applicant_indemnity_cover1
      • applicant_opinion_letter1
      • applicant_approval_letter1
      • applicant_statement1
      • applicant_participating_countries(null)
      • applicant_addendum1
      • applicant_fees1
      • applicant_complete_form(null)
      • applicant_impd1
      • applicant_prev_data1
      • applicant_stability_data1
      • applicant_analysis_cert1
      • applicant_pictorial_sample1
      • applicant_gcp_training1
      • applicant_dsmb_charter1
      • applicant_detailed_budget1
      • applicant_indemnity_pi1
      • applicant_practice_license1
      • applicant_registration_ctr(null)
      • applicant_pan_african1
      • applicant_hard_copies(null)
      • applicant_signed_checklist1
      • statistical_analysis_plan1
      • applicant_contractual_agreement1
      • declaration_applicantOfficia quasi sunt ab ducimus eaque consectetur aut hic modi omnis
      • declaration_date110-01-2025
      • declaration_principal_investigatorCupidatat consectetur consequuntur fugiat labore necessitatibus dolore est saepe dolorem cumque aliquid aliqua In id quibusdam accusamus
      • declaration_date209-01-2025
      • placebo_presentYes
      • study_objectives<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • principal_inclusion_criteria<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • principal_exclusion_criteria<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • primary_end_points<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • scope_diagnosis1
      • scope_prophylaxis0
      • scope_therapy0
      • scope_safety0
      • scope_efficacy0
      • scope_pharmacokinetic0
      • scope_pharmacodynamic1
      • scope_bioequivalence0
      • scope_dose_response1
      • scope_pharmacogenetic0
      • scope_pharmacogenomic0
      • scope_pharmacoecomomic1
      • scope_others1
      • scope_others_specifyIn odit voluptate fu
      • trial_human_pharmacology0
      • trial_administration_humans1
      • trial_bioequivalence_study0
      • trial_other1
      • trial_other_specifyVoluptas veniam ut
      • trial_therapeutic_exploratory0
      • trial_therapeutic_confirmatory1
      • trial_therapeutic_use1
      • design_controlledYes
      • site_capacity(null)
      • staff_numbers<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • other_details_explanation<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • other_details_regulatory_notapproved<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • other_details_regulatory_approved<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • other_details_regulatory_rejected
      • other_details_regulatory_halted
      • estimated_durationTempore id architecto quaerat ad vel
      • design_controlled_randomisedNo
      • design_controlled_openYes
      • design_controlled_single_blindNo
      • design_controlled_double_blindYes
      • design_controlled_parallel_groupNo
      • design_controlled_cross_overYes
      • design_controlled_otherYes
      • design_controlled_specifyQuo magna rerum dolor et atque adipisci esse nostrum
      • design_controlled_comparatorAut qui perspiciatis rei
      • design_controlled_other_medicinalNo
      • design_controlled_placeboNo
      • design_controlled_medicinal_otherYes
      • design_controlled_medicinal_specifySed iste tempore quia tempore tempor repudiandae molestias explicabo Omnis cum et asperiores vel est
      • single_site_member_stateNo
      • location_of_area
      • single_site_physical_address
      • single_site_contact_person
      • single_site_telephone
      • multiple_sites_member_stateYes
      • multiple_countriesNo
      • multiple_member_states
      • number_of_sites6
      • multi_country_list
      • data_monitoring_committeeNo
      • total_enrolment_per_siteVitae voluptatem se
      • total_participants_worldwideAutem ut aut commodo quas eaque velit dolore proident adipisicing eaque lorem sunt doloribus dolor quo pariatur
      • population_less_than_18_yearsYes
      • population_uteroYes
      • population_preterm_newbornYes
      • population_newbornYes
      • population_infant_and_toddlerNo
      • population_childrenYes
      • population_adolescentNo
      • population_above_18Yes
      • population_adultNo
      • population_elderlyNo
      • gender_female1
      • gender_male0
      • subjects_healthyNo
      • subjects_patientsYes
      • subjects_vulnerable_populationsYes
      • subjects_women_child_bearingNo
      • subjects_women_using_contraceptionYes
      • subjects_pregnant_womenNo
      • subjects_nursing_womenYes
      • subjects_emergency_situationNo
      • subjects_incapable_consentYes
      • subjects_specifyId tempora omnis vol
      • subjects_othersYes
      • subjects_others_specifyUllam laborum Eos
      • investigator1_given_nameIlliana Ferguson
      • investigator1_middle_nameAllen Fox
      • investigator1_family_nameYolanda Rivera
      • investigator1_qualificationAut labore non sed sed aut iusto et asperiores eu ut ut do qui ullam aut obcaecati earum modi in
      • investigator1_professional_addressEst doloremque dolores adipisicing quidem laboris voluptates vitae ex
      • investigator1_telephone+1 (621) 831-1153
      • investigator1_emailqeryrilu@mailinator.com
      • organisations_transferred_Yes
      • number_participantsMinim dolor commodo
      • notification
      • approval_date13-01-2025
      • submitted1
      • deleted0
      • deleted_date(null)
      • deactivated0
      • date_submitted22-01-2025
      • unsubmitted1
      • initial_date_submitted22-01-2025
      • admin_stopped0
      • admin_stopped_reason(null)
      • approved2
      • approved_reasonThis is approved
      • approved_date(null)
      • final_report(null)
      • implication_results(null)
      • quantity_imported(null)
      • quantity_dispensed(null)
      • quantity_destroyed(null)
      • quantity_exported(null)
      • balance_site(null)
      • final_date(null)
      • ecitizen_invoice324073
      • modified2025-02-13 08:07:31
      • created2025-01-22 10:39:23
    • InvestigatorContact(array)
      • 0(array)
        • id91
        • application_id158
        • given_nameHiroko Lewis
        • middle_nameTatyana Medina
        • family_nameCastor Gallagher
        • qualificationQuis molestiae voluptate aut aliquam velit est consequat Asperiores possimus et neque molestias aliqua Omnis voluptas non dolor nulla laudantium
        • professional_addressNisi qui dolor optio tempore quisquam laborum Suscipit
        • telephone+1 (322) 766-3057
        • emailtipyhuqo@mailinator.com
        • created2025-01-13 12:13:08
        • modified2025-02-13 08:07:31
    • SiteDetail(array)
      • 0(array)
        • id128
        • application_id158
        • county_id42
        • site_nameMiranda Alvarez
        • physical_addressAut ad quasi commodi non sint libero enim eos consequatur corrupti harum non
        • contact_detailsP.O. Box 86856
        • contact_personVoluptatibus molestias eligendi non repudiandae quis ipsa minim quia nostrum ut nisi possimus veniam
        • site_capacity(null)
        • misc(null)
        • created2013-06-27 10:49:32
        • modified2025-02-13 08:07:31
        • County(array)
          • id42
          • county_nameKisumu
          • created2012-06-15 10:27:02
          • modified2012-06-15 10:27:02
    • Sponsor(array)
      • 0(array)
        • id39
        • application_id158
        • sponsorEnim sint voluptatem eos nobis reiciendis dolore et qui corrupti quod minim pariatur Possimus
        • sponsor_typeLocal Kenyan Investigator
        • contact_personDolorem mollitia id quis provident error voluptatem voluptate
        • addressDolore laborum delectus dolor corrupti rerum aut magnam impedit quia cillum et cupiditate aliquid sapiente
        • telephone_number+1 (666) 325-1183
        • fax_number+1 (314) 248-5575
        • cell_number+1 (134) 102-6236
        • email_addresstuhokelyh@mailinator.com
        • created2025-01-13 12:13:08
        • modified2025-02-13 08:07:31
  • 4(array)
    • Application(array)
      • id159
      • user_id86
      • application_id118
      • is_child1
      • trial_status_id(null)
      • total_sites5
      • abstract_of_study<p>\n <em>Background:</em> The Novacov-24 virus, a newly identified respiratory pathogen, has raised global health concerns due to its rapid spread and potential for severe illness. Effective antiviral treatments are urgently needed to reduce symptom severity, prevent complications, and lower hospitalization rates.</p>\n<p>\n <em>Objective:</em> This randomized, double-blind, placebo-controlled clinical trial aims to evaluate the efficacy and safety of <em>Virunex-3</em>, a novel antiviral agent, in reducing the severity and duration of symptoms in patients infected with the Novacov-24 virus.</p>\n<p>\n <em>Methods:</em> A total of 500 adult participants with confirmed Novacov-24 infection will be enrolled. Participants will be randomly assigned to receive either <em>Virunex-3</em> (100 mg orally, once daily for 7 days) or a placebo. Primary outcomes will include the reduction of viral load and symptom resolution within 7 days. Secondary outcomes will assess hospitalization rates, need for mechanical ventilation, and mortality. Adverse events and treatment safety will also be monitored.</p>\n<p>\n <em>Expected Outcomes:</em> The study aims to determine whether <em>Virunex-3</em> can effectively reduce symptoms and improve patient recovery while ensuring safety. If successful, this trial could contribute to the development of a new standard of care for Novacov-24 infection.</p>\n<p>\n <em>Conclusion:</em> By assessing both the effectiveness and safety of <em>Virunex-3</em>, this trial will provide valuable insights into managing Novacov-24 and preventing severe health outcomes.</p>\n
      • study_title<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • laymans_summary<p>\n This study is designed to test a new antiviral medication called <em>Virunex-3</em> to see if it can help people recover faster from an illness caused by a newly identified virus called <em>Novacov-24</em>. Participants in the study will either receive <em>Virunex-3</em> or a placebo (a pill with no active ingredients) without knowing which one they are getting. The goal is to find out if <em>Virunex-3</em> can reduce symptoms more quickly, lower the need for hospital care, and prevent serious complications. The results will help doctors understand if this new treatment is safe and effective for fighting the virus.</p>\n
      • short_titleVirunex-3 Trial for Novacov-24
      • protocol_noECCT/25/01/09 - B
      • reference_no1234redwsqa
      • version_nov1
      • date_of_protocol01-01-2025
      • study_drugVirunex-3
      • disease_conditionNovacov-24 Virus Infection
      • product_type_biologicals1
      • product_type_proteins0
      • product_type_immunologicals1
      • product_type_vaccines0
      • product_type_hormones0
      • product_type_toxoid0
      • product_type_chemical0
      • product_type_medical_device0
      • product_type_chemical_name
      • product_type_medical_device_name
      • comparatorNo
      • comparator_name
      • comparator_registered
      • comparator_countries
      • ecct_not_applicable0
      • ecct_ref_number
      • email_addressjkiprotich@intellisoftkenya.com
      • applicant_covering_letter1
      • applicant_protocol1
      • applicant_patient_information1
      • applicant_investigators_brochure1
      • applicant_investigators_cv1
      • applicant_signed_declaration1
      • applicant_financial_declaration1
      • applicant_gmp_certificate1
      • applicant_indemnity_cover1
      • applicant_opinion_letter1
      • applicant_approval_letter1
      • applicant_statement1
      • applicant_participating_countries(null)
      • applicant_addendum1
      • applicant_fees1
      • applicant_complete_form(null)
      • applicant_impd1
      • applicant_prev_data1
      • applicant_stability_data1
      • applicant_analysis_cert1
      • applicant_pictorial_sample1
      • applicant_gcp_training1
      • applicant_dsmb_charter1
      • applicant_detailed_budget1
      • applicant_indemnity_pi1
      • applicant_practice_license1
      • applicant_registration_ctr(null)
      • applicant_pan_african1
      • applicant_hard_copies(null)
      • applicant_signed_checklist1
      • statistical_analysis_plan1
      • applicant_contractual_agreement1
      • declaration_applicantOfficia quasi sunt ab ducimus eaque consectetur aut hic modi omnis
      • declaration_date110-01-2025
      • declaration_principal_investigatorCupidatat consectetur consequuntur fugiat labore necessitatibus dolore est saepe dolorem cumque aliquid aliqua In id quibusdam accusamus
      • declaration_date209-01-2025
      • placebo_presentYes
      • study_objectives<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • principal_inclusion_criteria<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • principal_exclusion_criteria<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • primary_end_points<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • scope_diagnosis1
      • scope_prophylaxis0
      • scope_therapy0
      • scope_safety0
      • scope_efficacy0
      • scope_pharmacokinetic0
      • scope_pharmacodynamic1
      • scope_bioequivalence0
      • scope_dose_response1
      • scope_pharmacogenetic0
      • scope_pharmacogenomic0
      • scope_pharmacoecomomic1
      • scope_others1
      • scope_others_specifyIn odit voluptate fu
      • trial_human_pharmacology0
      • trial_administration_humans1
      • trial_bioequivalence_study0
      • trial_other1
      • trial_other_specifyVoluptas veniam ut
      • trial_therapeutic_exploratory0
      • trial_therapeutic_confirmatory1
      • trial_therapeutic_use1
      • design_controlledYes
      • site_capacity(null)
      • staff_numbers<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • other_details_explanation<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • other_details_regulatory_notapproved<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • other_details_regulatory_approved<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • other_details_regulatory_rejected
      • other_details_regulatory_halted
      • estimated_durationTempore id architecto quaerat ad vel
      • design_controlled_randomisedNo
      • design_controlled_openYes
      • design_controlled_single_blindNo
      • design_controlled_double_blindYes
      • design_controlled_parallel_groupNo
      • design_controlled_cross_overYes
      • design_controlled_otherYes
      • design_controlled_specifyQuo magna rerum dolor et atque adipisci esse nostrum
      • design_controlled_comparatorAut qui perspiciatis rei
      • design_controlled_other_medicinalNo
      • design_controlled_placeboNo
      • design_controlled_medicinal_otherYes
      • design_controlled_medicinal_specifySed iste tempore quia tempore tempor repudiandae molestias explicabo Omnis cum et asperiores vel est
      • single_site_member_stateNo
      • location_of_area
      • single_site_physical_address
      • single_site_contact_person
      • single_site_telephone
      • multiple_sites_member_stateYes
      • multiple_countriesYes
      • multiple_member_states668
      • number_of_sites9
      • multi_country_listAdipisicing et numqu
      • data_monitoring_committeeYes
      • total_enrolment_per_siteVitae voluptatem se
      • total_participants_worldwideAutem ut aut commodo quas eaque velit dolore proident adipisicing eaque lorem sunt doloribus dolor quo pariatur
      • population_less_than_18_yearsYes
      • population_uteroYes
      • population_preterm_newbornYes
      • population_newbornYes
      • population_infant_and_toddlerNo
      • population_childrenYes
      • population_adolescentNo
      • population_above_18Yes
      • population_adultNo
      • population_elderlyNo
      • gender_female1
      • gender_male0
      • subjects_healthyNo
      • subjects_patientsYes
      • subjects_vulnerable_populationsYes
      • subjects_women_child_bearingNo
      • subjects_women_using_contraceptionYes
      • subjects_pregnant_womenNo
      • subjects_nursing_womenYes
      • subjects_emergency_situationNo
      • subjects_incapable_consentYes
      • subjects_specifyId tempora omnis vol
      • subjects_othersYes
      • subjects_others_specifyUllam laborum Eos
      • investigator1_given_nameIlliana Ferguson
      • investigator1_middle_nameAllen Fox
      • investigator1_family_nameYolanda Rivera
      • investigator1_qualificationAut labore non sed sed aut iusto et asperiores eu ut ut do qui ullam aut obcaecati earum modi in
      • investigator1_professional_addressEst doloremque dolores adipisicing quidem laboris voluptates vitae ex
      • investigator1_telephone+1 (621) 831-1153
      • investigator1_emailqeryrilu@mailinator.com
      • organisations_transferred_Yes
      • number_participantsMinim dolor commodo
      • notification
      • approval_date13-01-2025
      • submitted1
      • deleted0
      • deleted_date(null)
      • deactivated0
      • date_submitted22-01-2025
      • unsubmitted1
      • initial_date_submitted22-01-2025
      • admin_stopped0
      • admin_stopped_reason(null)
      • approved2
      • approved_reasonThis is approved
      • approved_date(null)
      • final_report(null)
      • implication_results(null)
      • quantity_imported(null)
      • quantity_dispensed(null)
      • quantity_destroyed(null)
      • quantity_exported(null)
      • balance_site(null)
      • final_date(null)
      • ecitizen_invoice324073
      • modified2025-02-13 08:07:46
      • created2025-01-22 11:13:13
    • InvestigatorContact(array)
      • 0(array)
        • id92
        • application_id159
        • given_nameHiroko Lewis
        • middle_nameTatyana Medina
        • family_nameCastor Gallagher
        • qualificationQuis molestiae voluptate aut aliquam velit est consequat Asperiores possimus et neque molestias aliqua Omnis voluptas non dolor nulla laudantium
        • professional_addressNisi qui dolor optio tempore quisquam laborum Suscipit
        • telephone+1 (322) 766-3057
        • emailtipyhuqo@mailinator.com
        • created2025-01-13 12:13:08
        • modified2025-02-13 08:07:46
    • SiteDetail(array)
      • 0(array)
        • id1710
        • application_id159
        • county_id38
        • site_nameAhmed Trujillo
        • physical_addressDolorum dolores necessitatibus minus magna quo velit eveniet temporibus accusantium eveniet maxime reprehenderit consectetur ipsum ea aut
        • contact_detailsP.O. Box 10
        • contact_personExcepturi culpa dolore vero ut blanditiis aliquam error exercitation dolore reiciendis harum molestiae molestiae magnam fugit
        • site_capacity(null)
        • misc(null)
        • created2025-01-13 12:13:08
        • modified2025-02-13 08:07:46
        • County(array)
          • id38
          • county_nameVihiga
          • created2012-06-15 10:26:37
          • modified2012-06-15 10:26:37
    • Sponsor(array)
      • 0(array)
        • id40
        • application_id159
        • sponsorEnim sint voluptatem eos nobis reiciendis dolore et qui corrupti quod minim pariatur Possimus
        • sponsor_typeLocal Kenyan Investigator
        • contact_personDolorem mollitia id quis provident error voluptatem voluptate
        • addressDolore laborum delectus dolor corrupti rerum aut magnam impedit quia cillum et cupiditate aliquid sapiente
        • telephone_number+1 (666) 325-1183
        • fax_number+1 (314) 248-5575
        • cell_number+1 (134) 102-6236
        • email_addresstuhokelyh@mailinator.com
        • created2025-01-13 12:13:08
        • modified2025-02-13 08:07:46
• page_options(array)
  • 55
  • 1010
• redir
• $request->data(array)
  • Application(empty)
• $this->validationErrors(array)
  • Permission(empty)
  • Aro(empty)
  • Aco(empty)
  • Application(empty)
  • User(empty)
  • TrialStatus(empty)
  • InvestigatorContact(empty)
  • Sponsor(empty)
  • SiteDetail(empty)
  • County(empty)
• Loaded Helpers(array)
  • 0Html
  • 1Form
  • 2Session
  • 3Text
  • 4Number
  • 5SimpleGraph
  • 6Paginator
  • 7DebugTimer
  • 8Toolbar
  • 9HtmlToolbar

App Constants

CakePHP Constants

PHP Environment

Included Files

Include Paths

• 0/var/www/ctr/app/Plugin/Media/Lib/mm/src
• 1/var/www/ctr/lib
• 3/usr/share/php
• 4-> /var/www/ctr/lib/Cake/

Included Files

• core(array)
  • Behavior(array)
    • 0CORE/Model/Behavior/TreeBehavior.php
    • 1CORE/Model/Behavior/ContainableBehavior.php
    • 2CORE/Model/Behavior/AclBehavior.php
  • Cache(array)
    • 0CORE/Cache/Cache.php
    • 1CORE/Cache/Engine/FileEngine.php
    • 2CORE/Cache/CacheEngine.php
  • Component(array)
    • 0CORE/Controller/Component/AclComponent.php
    • 1CORE/Controller/Component/Acl/DbAcl.php
    • 2CORE/Controller/Component/Acl/AclInterface.php
    • 3CORE/Controller/Component/AuthComponent.php
    • 4CORE/Controller/Component/RequestHandlerComponent.php
    • 5CORE/Controller/Component/SessionComponent.php
    • 6CORE/Controller/Component/PaginatorComponent.php
  • Config(array)
    • 0CORE/Config/routes.php
    • 1CORE/Config/config.php
  • Controller(array)
    • 0CORE/Controller/Controller.php
    • 1CORE/Controller/ComponentCollection.php
    • 2CORE/Controller/Component.php
  • Datasource(array)
    • 0CORE/Model/Datasource/CakeSession.php
    • 1CORE/Model/Datasource/Database/Mysql.php
    • 2CORE/Model/Datasource/DboSource.php
    • 3CORE/Model/Datasource/DataSource.php
  • Error(array)
    • 0CORE/Error/exceptions.php
    • 1CORE/Error/ErrorHandler.php
  • I18n(array)
    • 0CORE/I18n/I18n.php
    • 1CORE/I18n/L10n.php
  • Log(array)
    • 0CORE/Log/CakeLog.php
    • 1CORE/Log/LogEngineCollection.php
    • 2CORE/Log/Engine/FileLog.php
    • 3CORE/Log/Engine/BaseLog.php
    • 4CORE/Log/CakeLogInterface.php
  • Model(array)
    • 0CORE/Model/ConnectionManager.php
    • 1CORE/Model/Permission.php
    • 2CORE/Model/Model.php
    • 3CORE/Model/BehaviorCollection.php
    • 4CORE/Model/Aro.php
    • 5CORE/Model/AclNode.php
    • 6CORE/Model/Aco.php
    • 7CORE/Model/ModelBehavior.php
  • Network(array)
    • 0CORE/Network/CakeRequest.php
    • 1CORE/Network/CakeResponse.php
  • Other(array)
    • 0CORE/bootstrap.php
    • 1CORE/basics.php
    • 2CORE/Core/App.php
    • 3CORE/Core/Configure.php
    • 4CORE/Core/CakePlugin.php
    • 5CORE/Event/CakeEventListener.php
    • 6CORE/Event/CakeEvent.php
    • 7CORE/Event/CakeEventManager.php
    • 8CORE/Core/Object.php
  • Routing(array)
    • 0CORE/Routing/Dispatcher.php
    • 1CORE/Routing/Filter/AssetDispatcher.php
    • 2CORE/Routing/DispatcherFilter.php
    • 3CORE/Routing/Filter/CacheDispatcher.php
    • 4CORE/Routing/Router.php
    • 5CORE/Routing/Route/CakeRoute.php
    • 6CORE/Routing/Route/PluginShortRoute.php
  • Utility(array)
    • 0CORE/Utility/Hash.php
    • 1CORE/Utility/Inflector.php
    • 2CORE/Utility/ObjectCollection.php
    • 3CORE/Utility/Debugger.php
    • 4CORE/Utility/String.php
    • 5CORE/Utility/ClassRegistry.php
    • 6CORE/Utility/Set.php
    • 7CORE/Utility/Sanitize.php
  • View(array)
    • 0CORE/View/HelperCollection.php
• app(array)
  • Behavior(array)
    • 0APP/Model/Behavior/SoftDeleteBehavior.php
  • Config(array)
    • 0APP/Config/core.php
    • 1APP/Config/bootstrap.php
    • 2APP/Config/routes.php
    • 3APP/Config/database.php
  • Controller(array)
    • 0APP/Controller/ApplicationsController.php
    • 1APP/Controller/AppController.php
  • Model(array)
    • 0APP/Model/AppModel.php
    • 1APP/Model/Application.php
    • 2APP/Model/User.php
    • 3APP/Model/TrialStatus.php
    • 4APP/Model/InvestigatorContact.php
    • 5APP/Model/Sponsor.php
    • 6APP/Model/SiteDetail.php
    • 7APP/Model/County.php
  • Other(array)
    • 0APP/webroot/index.php
• plugins(array)
  • CakePdf(array)
    • Config(array)
      • 0CakePdf/Config/bootstrap.php
      • 1CakePdf/Config/routes.php
  • CakeResque(array)
    • Config(array)
      • 0CakeResque/Config/bootstrap.php
    • Plugin(array)
      • 0CakeResque/Lib/CakeResque.php
      • 1CakeResque/vendor/kamisama/php-resque-ex/lib/Resque.php
      • 2CakeResque/vendor/kamisama/php-resque-ex/lib/Resque/Event.php
      • 3CakeResque/vendor/kamisama/php-resque-ex/lib/Resque/Exception.php
  • DebugKit(array)
    • Component(array)
      • 0DebugKit/Controller/Component/ToolbarComponent.php
    • Plugin(array)
      • 0DebugKit/Lib/DebugMemory.php
      • 1DebugKit/Lib/Panel/HistoryPanel.php
      • 2DebugKit/Lib/DebugPanel.php
      • 3DebugKit/Lib/Panel/SessionPanel.php
      • 4DebugKit/Lib/Panel/RequestPanel.php
      • 5DebugKit/Lib/Panel/SqlLogPanel.php
      • 6DebugKit/Lib/Panel/TimerPanel.php
      • 7DebugKit/Lib/Panel/LogPanel.php
      • 8DebugKit/Lib/Log/Engine/DebugKitLog.php
      • 9DebugKit/Lib/Panel/VariablesPanel.php
      • 10DebugKit/Lib/Panel/EnvironmentPanel.php
      • 11DebugKit/Lib/Panel/IncludePanel.php
      • 12DebugKit/Lib/DebugTimer.php
  • Media(array)
    • Config(array)
      • 0Media/Config/bootstrap.php
    • Plugin(array)
      • 0Media/Lib/mm/src/Mime/Type.php
      • 1Media/Lib/mm/src/Mime/Type/Magic/Adapter/Fileinfo.php
      • 2Media/Lib/mm/src/Mime/Type/Magic/Adapter.php
      • 3Media/Lib/mm/src/Mime/Type/Glob/Adapter/Memory.php
      • 4Media/Lib/mm/src/Mime/Type/Glob/Adapter.php
      • 5Media/Lib/mm/src/Media/Process.php
      • 6Media/Lib/mm/src/Media/Info.php
  • Search(array)
    • Component(array)
      • 0Search/Controller/Component/PrgComponent.php
    • Behavior(array)
      • 0Search/Model/Behavior/SearchableBehavior.php
  • Shim(array)
    • Config(array)
      • 0Shim/Config/bootstrap.php
  • Tools(array)
    • Config(array)
      • 0Tools/Config/bootstrap.php